AbbVie was created through a spinoff from Abbott Laboratories in 2013
Humira is the world’s #1 global pharmaceutical product by a large margin
AbbVie acquired Allergan, the maker of Botox in 2020, hence the huge jump in revenues and the change in the segment classifications
Dividend per share | 5.92 |
Dividend yield | 4.08% |
Payout frequency | Quarterly |
Maximum yield | 7.32% |
Average yield | 4.73% |
Minimum yield | 3.16% |
Discount to avg yield | -15.86% |
Upside potential | -13.69% |
Yield as % of max yield | 55.78% |
Dividend yield | 4.08% |
Current yield distribution | 71.27% |
Yield at 100% (Min) | 3.16% |
Yield at 90% | 3.71% |
Yield at 80% | 3.95% |
Yield at 50% (Median) | 4.80% |
Yield at 20% | 5.39% |
Yield at 10% | 5.77% |
Yield at 0% (Max) | 7.32% |
Years of growth | 9 years |
CCC status | Dividend Challenger |
Dividend per share | 5.92 |
Payout frequency | Quarterly |
Ex-div date | 12 Jan 2023 |
EPS (TTM) | 7.55 |
EPS (1y forward) | 11.74 |
EPS growth (5y) | 36.80% |
EPS growth (5y forward) | 8.27% |
ABBV | S&P500 | |
DGR MR | 4.96% | 11.59% |
DGR TTM | 7.53% | 10.54% |
DGR 3 years | 9.63% | 4.00% |
DGR 5 years | 17.11% | 5.65% |
DGR 10 years | - | 7.37% |
DGR 15 years | - | 5.83% |
Time since last change announced | 103 days |
EPS growth (5y) | 36.80% |
EPS growth (5y forward) | 8.27% |
EPS coverage | FCF coverage | |
TTM | 73.48% | 44.94% |
Average | - | - |
Forward | 50.43% | - |
Trailing P/E | 19.13 |
Price to OCF | 11.35 |
Price to FCF | 11.70 |
Price to EBITDA | 10.14 |
EV to EBITDA | 14.62 |
Price to Sales | 4.44 |
Price to Book | 16.00 |
EV to Sales | 6.40 |
Current share count | 1.77B |
EPS (TTM) | 7.55 |
FCF per share (TTM) | 12.34 |
Revenue (TTM) | 57.82B |
Gross profit (TTM) | 40.26B |
Operating income (TTM) | 17.69B |
Net income (TTM) | 13.41B |
EPS (TTM) | 7.55 |
EPS (1y forward) | 11.74 |
Gross margin (TTM) | 69.62% |
Operating margin (TTM) | 30.59% |
Profit margin (TTM) | 23.19% |
Cash | 11.83B |
Net receivables | 10.74B |
Total current assets | 30.36B |
Goodwill | 31.73B |
Intangible assets | 68.72B |
Property, plant and equipment | 0.00 |
Total assets | 141.32B |
Accounts payable | 23.50B |
Short/Current long term debt | 69.61B |
Total current liabilities | 32.71B |
Total liabilities | 125.30B |
Shareholder's equity | 16.03B |
Net tangible assets | -84.46B |
Operating cash flow (TTM) | 22.59B |
Capital expenditures (TTM) | 669.00M |
Free cash flow (TTM) | 21.92B |
Dividends paid (TTM) | 9.85B |
Return on Equity | 83.65% |
Return on Assets | 9.49% |
Return on Invested Capital | 15.66% |
Cash Return on Invested Capital | 25.60% |
Open | 145.74 |
Daily high | 146.33 |
Daily low | 144.81 |
Daily Volume | 3.77M |
All-time high | 174.96 |
1y analyst estimate | 162.50 |
Beta | 0.62 |
EPS (TTM) | 7.55 |
Dividend per share | 5.92 |
Ex-div date | 12 Jan 2023 |
Next earnings date | 9 Feb 2023 |
ABBV | S&P500 | |
Current price drop from All-time high | -17.11% | -14.21% |
Highest price drop | -48.88% | -56.47% |
Date of highest drop | 15 Aug 2019 | 9 Mar 2009 |
Avg drop from high | -14.22% | -11.49% |
Avg time to new high | 17 days | 13 days |
Max time to new high | 975 days | 1805 days |